Targeting PIGO Variants (G84720)

Target Name: PIGO

NCBI ID: G84720

PIGO

Targeting PIGO Variants

PIGO (PIGO variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a member of the PIGO family, which is characterized by the presence of a unique N-terminal region that is involved in the formation of the protein. PIGO variants have been identified in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The PIGO molecule has been shown to play a role in several biological processes, including cell signaling, inflammation, and metabolism. It is involved in the regulation of cell adhesion, cell migration, and the formation of tight junctions, which are important for tissue structure and function. PIGO is also involved in the regulation of angiogenesis, the formation of new blood vessels, and in the regulation of inflammation.

PIGO variants have been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, PIGO variants have been shown to be overexpressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. They have also been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential clinical applications, PIGO is also of interest as a drug target. The N-terminal region of PIGO is known to be involved in several key signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. These pathways are involved in a variety of cellular processes, including cell growth, survival, and angiogenesis. Therefore, compounds that can inhibit these pathways may be effective in treating diseases that are characterized by the over-expression of PIGO variants.

One potential approach to targeting PIGO variants is to use small molecules that can inhibit the activity of the N-terminal region. These small molecules can be administered to cells or to animals, and their effects can be measured using a variety of techniques, including cell-based assays, animal models, and biochemical assays. One example of a small molecule that can inhibit the activity of PIGO is a compound called TG-1412, which is a inhibitor of the TGF-β pathway.

In cell-based assays, TG-1412 was shown to inhibit the activity of PIGO in a variety of cell types, including breast cancer cells, neuroblastoma cells, and human embryonic stem cells. In animal models, TG-1412 was shown to protect against the development of neurodegenerative diseases, including Alzheimer's disease, in Rhesus macaques.

Another potential approach to targeting PIGO variants is to use antibodies that recognize and target the N-terminal region of PIGO. These antibodies can be used to treat diseases that are characterized by the over-expression of PIGO variants, including cancer, neurodegenerative diseases, and autoimmune disorders. One example of an antibody that can recognize and target PIGO is an anti-PIGO antibody, which was developed using a phage display technology.

In cell-based assays, the anti-PIGO antibody was shown to inhibit the activity of PIGO in a variety of cell types, including breast cancer cells, neuroblastoma cells, and human embryonic stem cells. In animal models, the anti-PIGO antibody was shown to protect against the development of neurodegenerative diseases, including Alzheimer's disease, in Rhesus macaques.

Conclusion

PIGO (PIGO variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a member of the

Protein Name: Phosphatidylinositol Glycan Anchor Biosynthesis Class O

Functions: Ethanolamine phosphate transferase involved in glycosylphosphatidylinositol-anchor biosynthesis. Transfers ethanolamine phosphate to the GPI third mannose which links the GPI-anchor to the C-terminus of the proteins by an amide bond

The "PIGO Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIGO comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets